Condition: Stroke · Cognitive Decline · Sponsor: Hospital Moinhos de Vento
This study is a phase III, prospective, placebo-controlled randomized clinical trial involving 8,518 subjects with low to moderate stroke risk, followed for 3 years in Brazil. Participants will be randomized to receive either the polypill (valsartan 80 mg, amlodipine 5 mg, and rosuvastatin 10 mg), with dose adjustment of amlodipine to 2.5 mg for patients experiencing adverse events, or a placebo, and to either use the Stroke Riskometer for lifestyle modification or receive usual care. The purpose of the study is to test whether the polypill, alone or in combination with lifestyle modification, will reduce the incidence of stroke and cognitive impairment in this population.
This description comes directly from the study's public registry record.
Sheila CO Martins, PhD · 5551999628467 · sheila@redebrasilavc.org.br
Thais L Secchi, MSc · 5551998977789 · thais.secchi@hmv.org.br
Always discuss trial participation with your own doctor first.
| Unidade de Saúde Santa Cecília / Hospital de Clínicas de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Hospital Moinhos de Vento | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05155137